Back to EZorb Newsletter Index

In this issue:

1. Share Success: Letters From Readers
2. Research News: Breast Cancer Drugs May Ward Off Alzheimer’s Disease
3. Useful Links
4. What Are Others Saying About EZorb and Marvlix?

Letter I: From Joyce
Received at Testimonial Submit Form Tuesday, March 24, 2020 at 06:41:53
(Unedited)

Hi, my name is Joyce.

I found you on my own after extensive searches on web. I haven't had good experience with Dr's since diagnosed diabetes. No one seems to know what type I'm being a Guinness pig.

I had problems last year with kidneys and found your site. I took Marvlix and got good lab results after couple months.

I seem to have the same problem this year and just ordered 1 bottle till I can get your 6 pack. I think I stopped taking them too soon.

I also want to take your calcium as I'm losing my hair. Love your product and look forward to calcium one too.

Blessings to you and yours,
Joy

Letter II: From Anonymous
Received at Testimonial Submit Form Saturday, February 08, 2020 at 23:48:46
(Unedited)

Hi, my name is Vesta C.

I had very painful heel spurs. I ran across this ad about Ezorb and decided to give it a try.

I ordered 2 bottles. I took them 5 in the am, and 5 in the evening. It took me about 3 bottles of the ezorb before the pain went completely away. The pain was so bad at times I had to use a cane just to get around when I first got up out of a chair or out of bed.

The pain is completely gone. I ordered 3 bottles the second order.

I am so thankful I tried Ezorb. I was not looking forward to going to a foot dr. They would want to do surgery on my foot. My primary Dr. was going to send me to one but I told him I would like to give this a try first.

Praise The Lord! I didn't have to go to one. Thank you so much!

This newsletter is now read by over 120,000 subscribers worldwide. Success stories you have contributed over the years have had a great impact on many people's life.

Please email your story to sharesuccess @ ezorbonline.com or simply post it at Testimonial Submit Form. Your personal information will never be revealed to the public.

Research suggests that women who use hormone-modulating breast cancer treatments (HMTs) such as tamoxifen or aromatase inhibitors (AIs) may experience a reduced risk for neurodegenerative disease (NDD).

“As we advance in our abilities to prevent, treat, and cure cancer, discussions around optimal care will need to include understanding the long-term outcomes of therapy selection for age-related NDDs,” explain Roberta Diaz Brinton, from the University of Arizona in Tucson, USA, and co-investigators.

“The fact that breast cancer is the second most common cancer in women (after skin cancer) and that women are disproportionately affected by AD [Alzheimer’s disease] and related dementia provides us with an opportunity to reduce the global disease burden of NDDs.”

The team analyzed information for 57,843 US breast cancer patients aged 45 years or older. The women were registered in the Humana insurance claims database between 2007 and 2017, and followed up for a mean of 5.5 years.

Around a third (31.3%) of these patients received tamoxifen, raloxifene, nonsteroidal AIs (anastrozole or letrozole), or a steroidal AI (exemestane), the researchers say in JAMA Network Open.

Propensity score-matched analysis revealed that women who received HMT were significantly less likely to be diagnosed with a NDD than those who did not, at 12.5% versus 14.3% and a relative risk (RR) of 0.89.

The difference in NDD diagnosis was largely explained by the diagnostic rates of AD (4.9 vs 6.0%, RR=0.82) and dementia (10.4 vs 11.8%, RR=0.88); by contrast, there was no significant association between HMT use and non-AD dementias, such as vascular dementia.

Noting that the analysis controlled for cerebrovascular and respiratory diseases, the authors suggest that there may be “a potential specific biological mechanism associated with estrogen loss in the brain in the pathophysiology of AD.” But they caution that the results may also be “due to a stronger association of cerebrovascular and respiratory disease with non-AD dementia.”

When patients were stratified by age, there was no significant difference in the risk for NDD or AD between women aged 65-69 years who did and did not receive HMT, whereas increasing age overall was associated with greater risk reduction for all NDDs in women taking HMT.

Further analysis indicated that tamoxifen (RR=0.84) and AIs (RR=0.83) were the HMTs associated with the greatest reductions in NDD.

Indeed, the researchers say that the impact of selective estrogen receptor modulators was “exclusively due to tamoxifen and not to raloxifene” and therefore may explain why earlier studies focused on raloxifene failed to show an association with AD.

While exemestane was associated with a greater reduction in the risk for AD or any dementia than anastrozole or letrozole, the team emphasizes that “both types of aromatase inhibitors exerted a protective association compared with patients with breast cancer who were not receiving any HMT.”

Original research was published in JAMA Netw Open 2020; 3: e201541.

EZorb - Frequently Asked Questions & Answers

EZorb Clinical Studies

Marvlix Benefits

Order Now

EZorb and Marvlix have restored confidence in thousands of men and women. It has brought happiness and healthy life to families around the world. Click here to read what people say about EZorb and Marvlix.

Back to EZorb Newsletter Index